

CURRICULUM VITAE

Name : **TCHAMGOUE YAMJE**

First name : **Serge**

Date of birth : August 4, 1970 in Yaoundé (Cameroun)

E-mail : stchamgoue@yahoo.fr

Phone : (237) 694 08 70 57 Or whatsapp (33) 6 87 56 40 16

Address : Quartier Bali, BP 3208 Douala-Cameroun

A. Personal Statement :

Doctor Serge Tchamgoue is a 50 years old Infectious Disease Specialist who has been involved since 2002 in training young doctors in Infectious disease field (HIV and Hepatitis) in Cameroun with the support of the Bordeaux University Hospital - France.

He participated in humanitarian care in north Cameroun (Kaélé) in 1997 and 1998. He is currently involved in screening Campaign and clinical care for HIV, Hepatis B & C infections in the littoral region of Cameroun.

In France, he has been involved since 2000 as co-investigator in Clinical Studies promoted by the "Agence Nationale de Recherche sur le SIDA et les Hépatites virales (French ANRS - Agency for Research on HIV and viral hepatitis), in the Aquitaine Co-3 Cohort.

B. Positions and Honors

- Current Vice President of the « National Network Against Hepatitis Virus in Cameroun » (Réseau National de Lutte Contre les Hépatites Virales au Cameroun)
- Current Head of Infectious Disease department of « Polyclinique Bordeaux Douala » in Douala-Cameroun
- Former Administrator (from 2002 to 2018) of the French Society Against HIV (Société Française de Lutte Contre le Sida) and head of "north/south" department of this Society
- Member of the International AIDS Society
- Member of French-Speaking Society of Infectious Diseases (Société de Pathologie Infectieuse de Langue Française, SPILF)
- Associated Member Of Cameroun Society of Hepatogastroenterologist Physicians
- Former « Chef de Clinique et Assistant des Hôpitaux » in Bordeaux University Hospital in France from 2000 to 2002

C. Main Contributions to Science

- 1) Sofosbuvir/ledipasvir : Efficacy and Tolerance in HCV positive patients naïve or pre-treated in Cameroun **EASL, International Liver meeting, Paris 2018**, Apr 12 (Poster). Tchamgoue S, Tzeuton C, Biwole M, Esmat G.
- 2) No increased Antiretroviral Potency by the addition of Enfuvirtide HAART regimen including boosted PI in naive HIVInfected Patients, ANRS Co3 Aquitaine cohort. **47e ICCAC Chicago USA(poster), September 2007**. Tchamgoué S et al
- 3) Tchamgoué S, Viillard JF, Texier J, Moinard M, Cipriano C, Pellegrin JL. Ostéomyélite, arthrite septique et abcès de la fesse à mycobactérie atypique chez une patiente infectée par le VIH-1. **Med Mal Inf 2004** ; 34 ;107-9
- 4) Tchamgoué S, Neau D, Ragnaud JM., Mégraud F. Extra-digestive manifestations of infection due to Campylobacter: a retrospective multicenter study of 121 cases. **41st ICAAC- September 22-25, 2001, Chicago, USA (poster)**
- 5) Broutet N, Tchamgoué S, Pereira A, Lamouliatte H, Salamon R, mégraud F. risk factors for failure of Helicobacter pylori – results of an individual data analysis of 2751 patients. **Aliment Pharmacol Ther 2003**; 17:99-109
- 6) Mercié P, Tchamgoué S, Dabis F, Pellegrin JL. Lipodystrophy in HIV-1 infected patients. **Lancet 1999**;354:867-68